About us

Our story

Founded in neuropathological expertise.

Our sophisticated diffusion analysis is based on neuropathology, and the correlations between microscopic data and MRI analysis. Based at the University of Oxford, Dr Steven Chance and Professor Mark Jenkinson combined their world class expertise to develop CDM® technology.

Today, our technology has breakthrough status for the assessment of brain health in dementia based on changes at the cellular level, which previously could only be analysed at post-mortem.

Dr Steven Chance (CEO & Co-Founder) was Associate Professor in Clinical Neurosciences at the University of Oxford. He has 20 years combined pathology and neuroscience experience researching the microscopic basis of brain disease. He is a world authority on the cortical disarray in dementia that is measured by the CDM® technology. He taught Medicine at Corpus Christi College and Human Sciences at Wadham College.

Professor Mark Jenkinson (Co-Founder) is at the University of Oxford and is one of the architects of the world’s leading MRI analysis software suite (FSL). He is one of the highest cited MRI authors globally and is editor of a new series of books on MR imaging.

Our team

Dr Steven Chance

CEO & Co-Founder

Melissa Strange

Chief Financial Officer

Ged Ridgway

Chief Scientific Officer

Nao Kamiya

Japan Liaison officer.

Julia Beltrao

Software engineer

Terry Pollard

Chief Operating Officer

Abhishek Roy

Senior software engineer

Helena Mistry

Commerical, US Sales

Jamie Hardwidge

Software Engineer/Data Scientist

Mirela Adamovici

Quality & Regulatory

Dr Mario Torso

Senior Scientist

Ian Hardingham

Chief Technology Officer

Dr Daniel A. Kaute

Business Development Advisor

Omar Ehsan

Chief Commercial Officer

Scientific Advisors